430 related articles for article (PubMed ID: 26384559)
1. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
3. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.
Magnani CF; Mezzanotte C; Cappuzzello C; Bardini M; Tettamanti S; Fazio G; Cooper LJN; Dastoli G; Cazzaniga G; Biondi A; Biagi E
Hum Gene Ther; 2018 May; 29(5):602-613. PubMed ID: 29641322
[TBL] [Abstract][Full Text] [Related]
6. Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.
Zhang R; Deng Q; Jiang YY; Zhu HB; Wang J; Zhao MF
Oncol Rep; 2019 Jun; 41(6):3455-3463. PubMed ID: 30942469
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
8. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
Brentjens RJ; Santos E; Nikhamin Y; Yeh R; Matsushita M; La Perle K; Quintás-Cardama A; Larson SM; Sadelain M
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5426-35. PubMed ID: 17855649
[TBL] [Abstract][Full Text] [Related]
9. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
[TBL] [Abstract][Full Text] [Related]
10. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.
Li H; Wang Y; Liu R; Li X; Zhang P; Chen P; Zhao N; Li B; Wang J; Tang Y
J Transl Med; 2024 May; 22(1):482. PubMed ID: 38773607
[TBL] [Abstract][Full Text] [Related]
11. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
12. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
13. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced leukemia in mice with mRNA engineered T cells.
Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
[TBL] [Abstract][Full Text] [Related]
15. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
17.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
18. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.
Almåsbak H; Walseng E; Kristian A; Myhre MR; Suso EM; Munthe LA; Andersen JT; Wang MY; Kvalheim G; Gaudernack G; Kyte JA
Gene Ther; 2015 May; 22(5):391-403. PubMed ID: 25652098
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
20. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.
Lapteva N; Gilbert M; Diaconu I; Rollins LA; Al-Sabbagh M; Naik S; Krance RA; Tripic T; Hiregange M; Raghavan D; Dakhova O; Rouce RH; Liu H; Omer B; Savoldo B; Dotti G; Cruz CR; Sharpe K; Gates M; Orozco A; Durett A; Pacheco E; Gee AP; Ramos CA; Heslop HE; Brenner MK; Rooney CM
Clin Cancer Res; 2019 Dec; 25(24):7340-7350. PubMed ID: 31558475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
